Werewolf Therapeutics, Inc.

HOWL

Werewolf Therapeutics, Inc.

HOWL

Insider Sentiment (TTM):

Last Purchase:2025-05-14Last Sale:2026-06-29Shares Purchased (TTM):0Shares Sold (TTM):3,949,636

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:13,979,976Shares Outstanding:48,596,817Institutional Ownership Pct.:28.77%

Earnings Market Reaction:

Filing Date:2026-07-31Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	22	46	57	66	78	92	111	123	135	139	134	130
Prepaid Expense And Other Assets Current	1	2	2	2	3	2	2	3	3	2	3	3
Assets Current	23	49	59	68	80	94	113	126	139	142	138	139
Other Receivables Net Current	-	-	-	-	-	-	0	0	1	1	1	6
Property Plant And Equipment Net	1	4	5	5	5	6	6	7	7	8	8	8
Restricted Cash Noncurrent	0	0	1	1	1	1	1	1	1	21	21	21
Operating Lease Right Of Use Asset	0	5	5	5	6	6	6	6	6	7	7	7
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	1	1
Assets	24	58	69	80	93	107	127	140	154	178	175	176
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	2	4	1	1	3	1	3	1	1	2	1	1
Accrued Liabilities Current	6	5	5	9	9	9	11	10	9	6	9	8
Operating Lease Liability Current	0	2	2	2	1	1	2	1	1	1	2	2
Notes Payable Current	0	29	28	6	2	-	0	0	0	12	7	2
Contract With Customer Liability Current	-	-	-	-	-	-	0	0	0	1	1	2
Liabilities Current	8	39	36	18	15	12	15	12	11	21	19	14
Operating Lease Liability Noncurrent	0	7	8	8	9	9	9	10	10	11	11	11
Long Term Notes Payable	-	-	0	22	25	27	26	26	25	28	33	38
Other Liabilities Noncurrent	-	-	-	-	-	-	-	-	-	-	0	0
Derivative Liabilities	-	-	-	-	-	-	-	3	3	-	-	-
Derivative Liabilities Noncurrent	0	0	1	3	3	3	3	-	-	-	0	-
Liabilities	8	46	45	50	51	50	54	51	50	60	63	64
Contract With Customer Liability Noncurrent	-	-	-	-	-	-	0	0	0	0	0	1
Stockholders Equity Inclu…
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	502	501	500	497	492	490	488	484	482	478	455	445
Retained Earnings Accumulated Deficit	-485	-489	-475	-467	-451	-433	-415	-394	-378	-360	-344	-332
Stockholders Equity	16	12	25	30	41	57	73	89	104	118	111	112
Liabilities And Stockholders Equity	24	58	69	80	93	107	127	140	154	178	175	176
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	49	49	49	47	45	45	45	44	44	43	39	36
Shares Outstanding	49	49	49	47	45	45	45	44	44	43	39	36

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-27.42%	-47.90%	-31.13%	-	-	-	-	-	-	-	-	-
2025	39.08%	17.24%	56.32%	2.27%	55.30%	-0.76%	-17.36%	-45.95%	-44.21%	21.13%	-34.06%	-51.22%
2024	-19.60%	-52.55%	-55.19%	16.76%	14.59%	62.16%	-10.71%	-30.80%	-38.39%	-44.60%	-28.17%	-3.97%
2023	-	-	-	-0.76%	-18.63%	-6.46%	31.82%	143.64%	145.91%	-4.00%	0.00%	-27.70%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	2.91	1.27	1.62	3.87	5.30	8.09	7.45	10.10	12.13	6.71	7.14	9.64
Quick Ratio	2.80	1.21	1.58	3.73	5.11	7.89	7.31	9.89	11.87	6.60	7.00	9.42
Working Capital	15.03M	10.22M	22.44M	50.57M	65.27M	82.79M	97.89M	113.37M	127.35M	121.07M	118.99M	124.82M
Leverage & Debt
Debt to Equity	0.48	3.76	1.80	1.69	1.23	0.87	0.73	0.57	0.48	0.51	0.57	0.57
Interest Coverage TTM	-6.87	-10.40	-11.50	-13.85	-14.39	-15.14	-15.81	-14.48	-13.48	-10.97	-12.23	-19.13
Debt Ratio	0.33	0.79	0.64	0.63	0.55	0.47	0.42	0.36	0.32	0.34	0.36	0.36
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.71	-1.14	-1.30	-1.59	-1.63	-1.62	-1.61	-1.42	-1.22	-1.00	-1.05	-1.05
Free Cash Flow Per Share TTM	-0.62	-1.07	-1.31	-1.39	-1.36	-1.34	-1.30	-1.07	-0.96	-0.93	-0.94	-1.15
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-52.68%	-22.30%	-13.75%	17.26%	36.13%	74.15%	88.70%	66.56%	31.20%	-17.58%	-30.56%	-205.75%
EPS Growth (1Y)	-56.20%	-28.33%	-18.78%	11.89%	31.71%	61.64%	55.24%	35.88%	7.19%	-31.10%	-43.77%	-188.28%
Valuation Metrics
P/E TTM	-0.51	-0.72	-0.48	-1.24	-0.67	-0.60	-0.91	-1.49	-1.98	-6.48	-3.68	-2.05
P/B TTM	1.07	3.32	1.18	3.05	1.18	0.76	0.87	1.04	1.02	2.29	1.24	0.68
Market Cap	17.50M	40.48M	29.18M	90.23M	49.03M	43.57M	64.13M	92.65M	106.19M	269.62M	137.60M	76.30M
Enterprise Value	-4.49M	21.96M	-539.02K	51.28M	-2.36M	-21.89M	-21.99M	-5.77M	-5.16M	169.84M	42.58M	-35.76M
Calculated Values
Free Cash Flow TTM	-30.15M	-51.94M	-60.29M	-63.64M	-60.95M	-59.98M	-56.44M	-46.85M	-41.81M	-38.72M	-33.38M	-40.99M
Net Debt	-21.99M	-18.52M	-29.72M	-38.95M	-51.39M	-65.46M	-86.12M	-98.43M	-111.35M	-99.77M	-95.02M	-112.06M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-29Sale

Owner: Evnin, Luke

Title: -

Shares: 157,084

Price/Share: $0.30

Value: $47,125.20

Shares Owned: 143,199

Relationship: Director

Ownership: Indirect

2026-06-17Sale

Owner: Ra, Capital Management, L…

Title: -

Shares: 416,911

Price/Share: $0.35

Value: $145,918.85

Shares Owned: 303,719

Relationship: TenPercentOwner

Ownership: Indirect

2026-06-16Sale

Owner: Ra, Capital Management, L…

Title: -

Shares: 149,625

Price/Share: $0.37

Value: $55,361.25

Shares Owned: 331,414

Relationship: TenPercentOwner

Ownership: Indirect

2026-06-11Sale

Owner: Kolchinsky, Peter, Ra Cap…

Title: -

Shares: 262,503

Price/Share: $0.38

Value: $99,751.14

Shares Owned: 361,229

Relationship: TenPercentOwner

Ownership: Indirect

2026-06-09Sale

Owner: Evnin, Luke

Title: -

Shares: 76,928

Price/Share: $0.37

Value: $28,463.36

Shares Owned: 300,283

Relationship: Director

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-29	Evnin, Luke	Director	-	Indirect	Sale	157,084	0.30	$47,125.20	143,199	4
2026-06-17	Ra, Capital Management, L…	TenPercentOwner	-	Indirect	Sale	416,911	0.35	$145,918.85	303,719	4
2026-06-16	Ra, Capital Management, L…	TenPercentOwner	-	Indirect	Sale	149,625	0.37	$55,361.25	331,414	4
2026-06-11	Kolchinsky, Peter, Ra Cap…	TenPercentOwner	-	Indirect	Sale	262,503	0.38	$99,751.14	361,229	4
2026-06-09	Evnin, Luke	Director	-	Indirect	Sale	76,928	0.37	$28,463.36	300,283	4
2026-06-08	Evnin, Luke	Director	-	Indirect	Sale	60,547	0.40	$24,218.80	377,211	4
2026-06-03	Evnin, Luke	Director	-	Indirect	Sale	29,749	0.42	$12,494.58	482,776	4
2026-05-29	Evnin, Luke	Director	-	Indirect	Sale	32,556	0.45	$14,650.20	622,579	4
2026-05-26	Evnin, Luke	Director	-	Indirect	Sale	67,950	0.47	$31,936.50	763,685	4
2026-05-19	Evnin, Luke	Director	-	Indirect	Sale	62,970	0.45	$28,336.50	1,041,342	4
2026-05-13	Evnin, Luke	Director	-	Indirect	Sale	44,679	0.54	$24,126.66	1,126,496	4
2026-05-12	Evnin, Luke	Director	-	Indirect	Sale	67,885	0.64	$43,446.40	1,171,175	4
2026-05-08	Ra, Capital Management, L…	TenPercentOwner	-	Indirect	Sale	376,526	0.71	$267,333.46	418,813	4
2026-05-07	Evnin, Luke	Director	-	Indirect	Sale	79,086	0.63	$49,824.18	1,578,749	4
2026-05-04	Evnin, Luke	Director	-	Indirect	Sale	47,963	0.72	$34,533.36	1,679,330	4
2026-04-29	Evnin, Luke	Director	-	Indirect	Sale	56,559	0.69	$39,025.71	1,953,949	4
2026-01-16	Evnin, Luke	Director	-	Indirect	Sale	38,782	0.54	$20,942.28	2,159,860	4
2026-01-15	Evnin, Luke	Director	-	Indirect	Sale	37,413	0.55	$20,577.15	2,198,642	4
2026-01-12	Evnin, Luke	Director	-	Indirect	Sale	58,980	0.57	$33,618.60	2,309,869	4
2026-01-07	Evnin, Luke	Director	-	Indirect	Sale	11,915	0.64	$7,625.60	2,401,243	4
2025-12-31	Evnin, Luke	Director	-	Indirect	Sale	24,962	0.62	$15,476.44	2,490,865	4
2025-12-29	Evnin, Luke	Director	-	Indirect	Sale	108,606	0.61	$66,249.66	2,550,674	4
2025-12-17	Evnin, Luke	Director	-	Indirect	Sale	9,983	1.14	$11,380.62	2,841,957	4
2025-12-12	Evnin, Luke	Director	-	Indirect	Sale	17,858	1.08	$19,286.64	2,890,128	4
2025-12-09	Evnin, Luke	Director	-	Indirect	Sale	44,570	1.01	$45,015.70	2,973,099	4
2025-12-04	Evnin, Luke	Director	-	Indirect	Sale	53,416	0.97	$51,813.52	3,068,278	4
2025-12-04	Mpm, Bioventures 2014 (B)…	Other	-	Indirect	Sale	83,230	0.97	$80,733.10	4,784,111	4
2025-12-04	Mpm, Bioimpact Llc, Mpm A…	Other	-	Indirect	Sale	83,230	0.97	$80,733.10	4,784,111	4
2025-12-01	Mpm, Asset Management Inv…	TenPercentOwner	-	Indirect	Sale	60,917	0.94	$57,261.98	4,983,843	4
2025-12-01	Ubs, Oncology Impact Fund…	TenPercentOwner	-	Indirect	Sale	60,917	0.94	$57,261.98	4,983,843	4
2025-12-01	Evnin, Luke	Director	-	Indirect	Sale	39,096	0.94	$36,750.24	3,196,463	4
2025-11-25	Evnin, Luke	Director	-	Indirect	Sale	27,297	0.92	$25,113.24	3,287,551	4
2025-11-25	Mpm, Oncology Innovations…	TenPercentOwner	-	Indirect	Sale	42,533	0.92	$39,130.36	5,125,770	4
2025-11-25	Mpm, Bioventures 2014 Gp …	TenPercentOwner	-	Indirect	Sale	42,533	0.92	$39,130.36	5,125,770	4
2025-11-20	Evnin, Luke	Director	-	Indirect	Sale	26,411	0.89	$23,505.79	3,413,127	4
2025-11-20	Mpm, Bioventures 2014 Llc…	TenPercentOwner	-	Indirect	Sale	41,152	0.89	$36,625.28	5,321,436	4
2025-11-20	Mpm, Oncology Innovations…	TenPercentOwner	-	Indirect	Sale	41,152	0.89	$36,625.28	5,321,436	4
2025-11-17	Mpm, Bioventures 2014 Llc…	TenPercentOwner	-	Indirect	Sale	57,061	0.95	$54,207.95	5,481,539	4
2025-11-17	Evnin, Luke	Director	-	Indirect	Sale	36,621	0.95	$34,789.95	3,515,880	4
2025-11-17	Mpm, Oncology Innovations…	TenPercentOwner	-	Indirect	Sale	57,061	0.95	$54,207.95	5,481,539	4
2025-11-12	Evnin, Luke	Director	-	Indirect	Sale	26,101	1.09	$28,450.09	3,650,433	4
2025-11-12	Ubs, Oncology Impact Fund…	TenPercentOwner	-	Indirect	Sale	40,669	1.09	$44,329.21	5,691,191	4
2025-11-12	Mpm, Bioventures 2014, L.…	TenPercentOwner	-	Indirect	Sale	40,669	1.09	$44,329.21	5,691,191	4
2025-11-06	Mpm, Bioimpact Llc, Mpm O…	TenPercentOwner	-	Indirect	Sale	54,452	1.21	$65,886.92	5,904,720	4
2025-11-06	Mpm, Bioventures 2014 Llc…	TenPercentOwner	-	Indirect	Sale	54,452	1.21	$65,886.92	5,904,720	4
2025-11-06	Evnin, Luke	Director	-	Indirect	Sale	34,947	1.21	$42,285.87	3,787,474	4
2025-11-03	Evnin, Luke	Director	-	Indirect	Sale	60,369	1.29	$77,876.01	3,943,359	4
2025-11-03	Mpm, Oncology Innovations…	TenPercentOwner	-	Indirect	Sale	94,063	1.29	$121,341.27	6,147,610	4
2025-11-03	Mpm, Asset Management Inv…	TenPercentOwner	-	Indirect	Sale	94,063	1.29	$121,341.27	6,147,610	4
2025-10-29	Mpm, Bioventures 2014 Llc…	TenPercentOwner	-	Indirect	Sale	134,240	1.55	$208,072.00	6,442,653	4
2025-10-29	Evnin, Luke	Director	-	Indirect	Sale	86,154	1.55	$133,538.70	4,132,715	4
2025-10-29	Ubs, Oncology Impact Fund…	TenPercentOwner	-	Indirect	Sale	134,240	1.55	$208,072.00	6,442,653	4
2025-05-14	Ra, Capital Nexus Fund Ii…	Director,TenPercentOwner	-	Indirect	Purchase	162,539	0.98	$159,288.22	6,237,482	4
2025-03-27	Mpm, Asset Management Llc…	TenPercentOwner	-	Indirect	Sale	4,386	1.05	$4,605.30	6,718,670	4
2025-03-27	Mpm, Asset Management Inv…	TenPercentOwner	-	Indirect	Sale	1,963	1.05	$2,061.15	3,208,793	4
2025-03-27	Evnin, Luke	Director,TenPercentOwner	-	Indirect	Sale	2,425	1.05	$2,546.25	4,309,860	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

28.77%

Inst. Shares: 13,979,976

Shares Outstanding: 48,596,817

2025-12-31

32.02%

Inst. Shares: 14,735,205

Shares Outstanding: 46,018,888

2025-09-30

45.86%

Inst. Shares: 21,004,766

Shares Outstanding: 45,804,042

2025-06-30

49.36%

Inst. Shares: 22,203,448

Shares Outstanding: 44,981,746

2025-03-31

60.53%

Inst. Shares: 27,135,568

Shares Outstanding: 44,827,159

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	13,979,976	48,596,817	28.77%
2025-12-31	14,735,205	46,018,888	32.02%
2025-09-30	21,004,766	45,804,042	45.86%
2025-06-30	22,203,448	44,981,746	49.36%
2025-03-31	27,135,568	44,827,159	60.53%
2024-12-31	27,845,315	43,332,088	64.26%
2024-09-30	31,621,554	43,704,836	72.35%
2024-06-30	31,762,064	43,521,406	72.98%
2024-03-31	31,929,379	41,607,279	76.74%
2023-12-31	27,457,952	35,646,572	77.03%
2023-09-30	23,749,822	35,653,924	66.61%
2023-06-30	23,921,810	35,557,701	67.28%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Werewolf Therapeutics, Inc. (HOWL) — SEC Financial Statements & Analysis

Werewolf Therapeutics, Inc. (HOWL) is a pharmaceutical preparations company, incorporated in DE. Werewolf Therapeutics, Inc. trades on Nasdaq as: HOWL. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Werewolf Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.48x, a Price-to-Book (P/B) ratio of 1.07x (TTM), at a market cap of $17.50M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.48x
P/B TTM: 1.07x
Market Cap: $17.50M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Werewolf Therapeutics, Inc. in?

Werewolf Therapeutics, Inc. (HOWL) operates in the Pharmaceutical Preparations industry.

What is HOWL's market cap?

Werewolf Therapeutics, Inc. (HOWL) has a market capitalization of $17.50M as of 2026-06-30.

What exchange does HOWL trade on?

Werewolf Therapeutics, Inc. (HOWL) trades on the Nasdaq.

Where is Werewolf Therapeutics, Inc. incorporated?

Werewolf Therapeutics, Inc. is incorporated in DE.